Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-04-08 Sale | 2024-04-09 4:25 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $54.17 | $3,743,605 | 1,153,263 (Direct) | View |
2024-04-01 Sale | 2024-04-02 4:06 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 4,000 | $58.66 | $234,640 | 407,473 (Indirect Direct) | View |
2024-03-19 Sale | 2024-03-20 5:18 pm | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 18,681 | $57.18 | $1,068,161 | 337,871 (Indirect Direct) | View |
2024-03-18 Sale | 2024-03-19 4:03 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 9,913 | $56.9 | $564,050 | 54,693 (Direct) | View |
2024-03-15 Sale | 2024-03-18 4:19 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 184 | $56.46 | $10,389 | 38,883 (Direct) | View |
2024-03-13 Sale | 2024-03-14 4:17 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 11,220 | $57.56 | $645,838 | 56,287 (Direct) | View |
2024-03-08 Sale | 2024-03-11 4:08 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $62.19 | $4,297,549 | 1,222,370 (Direct) | View |
2024-03-01 Sale | 2024-03-05 4:07 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 250,000 | $64.11 | $16,028,706 | 2,219,608 (Indirect Direct) | View |
2024-03-01 Sale | 2024-03-05 4:04 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 6,000 | $63.22 | $379,340 | 411,473 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 5:06 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 781 | $67.77 | $52,926 | 194,095 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 5:05 pm | Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer | 1,148 | $67.77 | $77,796 | 92,453 (Direct) | View |
2024-02-12 Sale | 2024-02-13 4:59 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 1,431 | $67.77 | $96,974 | 149,570 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 4:49 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 3,962 | $67.77 | $268,492 | 2,035,230 (Indirect Direct) | View |
2024-02-12 Sale | 2024-02-13 4:43 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 1,148 | $67.77 | $77,796 | 1,115,983 (Direct) | View |
2024-02-12 Sale | 2024-02-13 4:38 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 597 | $67.77 | $40,457 | 64,606 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:38 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 906 | $64.14 | $58,109 | 194,876 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 4:36 pm | Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer | 906 | $64.14 | $58,109 | 93,601 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:34 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 906 | $64.14 | $58,109 | 151,001 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 4:31 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 835 | $64.14 | $53,555 | 67,507 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:28 pm | Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer | 1,250 | $65.12 | $81,402 | 46,387 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:26 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 2,843 | $64.14 | $182,345 | 2,039,192 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 4:23 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 1,250 | $65.22 | $81,524 | 57,208 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:21 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 874 | $64.14 | $56,057 | 1,117,131 (Direct) | View |
2024-01-29 Sale | 2024-01-31 4:18 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 367 | $64.14 | $23,539 | 65,203 (Direct) | View |
2024-01-23 Sale | 2024-01-24 4:06 pm | Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer | 4,286 | $63.69 | $272,975 | 47,637 (Direct) | View |
2024-01-23 Sale | 2024-01-24 4:03 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 7,378 | $63.69 | $469,905 | 58,458 (Direct) | View |
2024-01-22 Sale | 2024-01-23 7:28 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 13,431 | $65 | $872,961 | 2,042,035 (Indirect Direct) | View |
2024-01-22 Sale | 2024-01-23 6:17 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 4,184 | $65 | $271,943 | 195,782 (Indirect Direct) | View |
2024-01-22 Sale | 2024-01-23 6:15 pm | Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer | 3,413 | $65 | $221,831 | 94,507 (Direct) | View |
2024-01-22 Sale | 2024-01-23 6:13 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 3,551 | $65 | $230,801 | 151,907 (Indirect Direct) | View |
2024-01-22 Sale | 2024-01-23 6:11 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 2,593 | $65 | $168,535 | 68,342 (Direct) | View |
2024-01-22 Sale | 2024-01-23 6:07 pm | Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer | 1,738 | $65 | $112,963 | 51,923 (Direct) | View |
2024-01-22 Sale | 2024-01-23 6:05 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 1,607 | $65 | $104,449 | 65,836 (Direct) | View |
2024-01-22 Sale | 2024-01-23 6:03 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 3,913 | $65 | $254,329 | 1,118,005 (Direct) | View |
2024-01-22 Sale | 2024-01-23 6:01 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 1,384 | $65 | $89,954 | 65,570 (Direct) | View |
2024-01-22 Sale | 2024-01-23 6:00 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 1,061 | $65 | $68,961 | 39,067 (Direct) | View |
2024-01-17 Sale | 2024-01-18 4:55 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 5,207 | $65.58 | $341,475 | 67,443 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-04-18 Gift | 2024-04-19 7:27 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 14,164 | $0 | 149,570 (Direct) | View |
2024-04-12 Exercise | 2024-04-15 4:09 pm | N/A 2028-12-31 | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 1,500 | $0 | 344,871 (Direct) | View |
2024-04-12 Exercise | 2024-04-15 4:09 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 1,500 | $13.19 | 344,871 (Direct) | View |
2024-04-08 Exercise | 2024-04-09 4:25 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $3.76 | 1,153,263 (Direct) | View |
2024-04-08 Exercise | 2024-04-09 4:25 pm | N/A 2026-02-07 | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $0 | 1,153,263 (Direct) | View |
2024-04-01 Exercise | 2024-04-02 4:06 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 4,000 | $10.03 | 407,473 (Direct) | View |
2024-04-01 Exercise | 2024-04-02 4:06 pm | N/A 2027-10-18 | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 4,000 | $0 | 407,473 (Direct) | View |
2024-03-08 Exercise | 2024-03-11 4:08 pm | N/A 2026-02-07 | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $0 | 1,222,370 (Direct) | View |
2024-03-08 Exercise | 2024-03-11 4:08 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 69,107 | $3.67 | 1,222,370 (Direct) | View |
2024-03-06 Exercise | 2024-03-08 07:45 am | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 3,762 | $13.85 | 197,857 (Direct) | View |
2024-03-06 Exercise | 2024-03-08 07:45 am | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 3,762 | $0 | 197,857 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:07 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 50,000 | $3.76 | 2,219,608 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:07 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 200,000 | $4.31 | 2,219,608 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:07 pm | N/A 2026-02-06 | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 250,000 | $0 | 2,219,608 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:04 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 6,000 | $10.03 | 411,473 (Direct) | View |
2024-03-01 Exercise | 2024-03-05 4:04 pm | N/A 2027-10-18 | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 6,000 | $0 | 411,473 (Direct) | View |